TALOPH(SH:600222)2024-04-25 09:21Financial Performance - The company's operating revenue for Q1 2024 was CNY 499,111,557.06, representing a decrease of 10.92% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 21,258,639.34, an increase of 477.28% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 18,959,139.12, up 449.09% from the previous year[3]. - The basic earnings per share for the period was CNY 0.0381, reflecting an increase of 486.15%[3]. - The company's total revenue for Q1 2024 was approximately RMB 498.29 million, representing a year-over-year decrease of 11.03%[12]. - Net profit for Q1 2024 reached ¥20,521,428.43, significantly up from ¥3,288,380.45 in Q1 2023, marking a growth of 524.5%[21]. - Earnings per share for Q1 2024 were ¥0.0381, compared to ¥0.0065 in Q1 2023, reflecting a substantial increase[22]. - The total comprehensive income for Q1 2024 was ¥11,842,601.45, a recovery from a loss of ¥26,330,990.10 in Q1 2023[22]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,652,921,928.38, a 2.13% increase from the end of the previous year[4]. - The total assets of the company as of March 31, 2024, amounted to RMB 3.65 billion, a slight increase from RMB 3.58 billion at the end of 2023[15]. - The total liabilities as of Q1 2024 amounted to ¥2,019,002,615.70, an increase from ¥1,953,466,408.19 in Q1 2023[17]. - The total equity attributable to shareholders of the parent company was ¥1,586,113,393.33, up from ¥1,578,493,578.60 in Q1 2023[17]. Cash Flow - The net cash flow from operating activities was negative CNY 115,823,793.88, a decrease of 25.53% compared to the same period last year[3]. - In Q1 2024, the cash inflow from operating activities was CNY 481,141,378.39, a decrease of 2.6% compared to CNY 495,801,337.20 in Q1 2023[23]. - The net cash flow from operating activities was -CNY 115,823,793.88, worsening from -CNY 92,268,340.56 in the same period last year[24]. - Cash inflow from investment activities totaled CNY 317,460,800.84, significantly increasing from CNY 62,926,917.78 in Q1 2023[24]. - The net cash flow from investment activities was CNY 100,273,498.41, compared to -CNY 19,638,810.19 in Q1 2023, indicating a positive turnaround[24]. - Cash inflow from financing activities was CNY 266,303,164.84, up from CNY 159,719,213.09 in the previous year[24]. - The net cash flow from financing activities was CNY 45,893,909.40, slightly down from CNY 48,985,479.47 in Q1 2023[24]. - The total cash and cash equivalents at the end of Q1 2024 were CNY 213,271,783.83, an increase from CNY 191,799,611.96 at the end of Q1 2023[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 56,451[9]. - The equity attributable to shareholders at the end of the reporting period was CNY 1,586,113,393.33, up 0.48% from the previous year[4]. Operational Metrics - The revenue from the Chinese herbal medicine segment increased by 22.38% year-over-year, reaching RMB 230.47 million[14]. - The gross margin for the pharmaceutical formulation segment was 46.28%, down 34.71% compared to the previous year[14]. - The company reported a gross margin of 27.29% for the overall business, which remained stable compared to the previous year[14]. - The inventory level was RMB 459.32 million, showing a marginal increase from RMB 455.50 million[15]. - The company’s long-term equity investments rose to RMB 158.25 million from RMB 140.63 million[15]. - The company’s accounts receivable increased to RMB 787.62 million from RMB 739.64 million[15]. - The company’s prepayments increased to RMB 94.85 million from RMB 75.31 million[15]. Expenses - Research and development expenses for Q1 2024 were ¥24,278,145.33, slightly up from ¥24,187,244.98 in Q1 2023[21]. - The company paid CNY 101,467,185.30 in employee compensation, a decrease of 6.7% from CNY 107,903,005.13 in Q1 2023[24]. - The company reported a cash outflow of CNY 18,864,324.47 for taxes, down from CNY 25,471,693.56 in the previous year[24]. - The company’s financial expenses increased to ¥14,388,510.52 in Q1 2024 from ¥12,680,779.23 in Q1 2023[21]. Non-Recurring Gains - The company recognized non-recurring gains of CNY 2,299,500.22 after tax, primarily from government subsidies and other non-operating income[4]. - The company reported an investment income of ¥2,593,567.11 in Q1 2024, compared to a loss of ¥1,738,337.26 in Q1 2023[21]. Accounting Standards - The company did not apply new accounting standards for the first time in 2024[25].